ArticleCureus2026
Carbetocin for the Prevention of Postpartum Hemorrhage: A Comparative Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPostpartum hemorrhage (PPH) remains a major obstetric emergency and a leading cause of maternal morbidity and mortality. Uterotonics administered during the third stage of labor play a crucial role in its prevention. Carbetocin has emerged as a potential alternative to oxytocin due to its prolonged uterotonic effect and improved pharmacological profile. The study aimed to evaluate the effectiveness and safety of carbetocin in the prevention of PPH and to compare its outcomes with oxytocin using a combined intramuscular and intravenous oxytocin regimen in women undergoing vaginal or caesarean delivery. MATERIALS AND
methodsThis prospective observational comparative study was conducted among 100 women (50 in each group) receiving either carbetocin (100 µg intramuscularly) or oxytocin (10 IU intramuscularly with additional intravenous infusion as per institutional protocol) immediately after delivery. Estimated blood loss, incidence of PPH (defined as ≥500 mL for vaginal delivery and ≥1000 mL for cesarean section), fall in hemoglobin, hemodynamic changes, and requirement for additional uterotonics were noted. Statistical analysis was performed, and a p-value <0.05 was considered significant.
resultsBaseline characteristics were comparable between groups. Mean estimated blood loss was significantly lower in the carbetocin group (410 ± 85 mL) compared to the oxytocin group (520 ± 110 mL; p<0.001). PPH occurred in three (6%) women in the carbetocin group versus 12 (24%) women in the oxytocin group (p=0.01). The mean fall in hemoglobin was lower with carbetocin (0.6 ± 0.4 g/dL vs 1.1 ± 0.6 g/dL; p<0.001). Additional uterotonics were required in two (4%) women receiving carbetocin compared to 11 (22%) women receiving oxytocin (p=0.007). Carbetocin was associated with better hemodynamic stability.
conclusionCarbetocin was associated with reduced blood loss, lower PPH incidence, and improved hemodynamic stability compared to oxytocin within the context of differing prophylactic regimens. However, larger randomized studies are required to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.